Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.
Tsujikawa T, Ohno K, Morita KI, Saburi S, Mitsuda J, Yoshimura K, Kimura A, Morimoto H, Ogi H, Shibata S, Akashi T, Kurata M, Imoto I, Shimizu Y, Kano S, Watanabe A, Yamazaki T, Asada Y, Hayashi R, Saito Y, Ozawa H, Tsukahara K, Oridate N, Sano D, Horii A, Ueki Y, Maruo T, Mukoyama N, Hanai N, Fukusumi T, Iwai H, Fujisawa T, Fujii T, Nibu KI, Iwae S, Ueda T, Chikuie N, Yasumatsu R, Matsuo M, Umeno H, Ono T, Masuda M, Toh S, Itoh K, Hirano S, Asakage T.
Tsujikawa T, et al. Among authors: yasumatsu r.
Front Immunol. 2024 Jul 29;15:1390873. doi: 10.3389/fimmu.2024.1390873. eCollection 2024.
Front Immunol. 2024.
PMID: 39136017
Free PMC article.